BSE: 0 | NSE: WALPAR | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Walpar Nutritions Ltd is a below average quality company.
The key valuation ratios of Walpar Nutritions Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Walpar Nutritions Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 3.4% | 6.4% | 5.4% | 12% | - |
| Value Creation Index ⓘ | -0.8 | -0.5 | -0.6 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 6.1 | 26.8 | 28.7 | 51.3 | 51 |
| Sales YoY Gr. | - | 340.9% | 7.3% | 78.8% | - |
| Adj EPS ⓘ | 0.2 | 0.5 | 0.3 | 1.1 | 1.2 |
| YoY Gr. | - | 104.4% | -27.7% | 232.4% | - |
| BVPS (₹) ⓘ | 6.9 | 12.1 | 12.4 | 14.2 | 19.2 |
| Adj Net Profit ⓘ | 0.2 | 0.4 | 0.3 | 1.1 | 1 |
| Cash Flow from Ops. ⓘ | 1.4 | -0.3 | 1.1 | 3.1 | - |
| Debt/CF from Ops. ⓘ | 4 | -13.8 | 2.9 | 0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 103.7% | 78.8% | ||||
| Adj EPS ⓘ | NA | NA | 70% | 232.4% | ||||
| BVPSⓘ | NA | NA | 27.5% | 14.1% | ||||
| Share Price | - | - | 12.5% | -50.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.2 | 5.4 | 2.8 | 8.6 | 7.1 |
| Op. Profit Mgn % ⓘ | 7.7 | 4 | 2.8 | 3.4 | NAN |
| Net Profit Mgn % ⓘ | 2.5 | 1.6 | 1.1 | 2.1 | 2.2 |
| Debt to Equity ⓘ | 1.2 | 0.4 | 0.3 | 0 | - |
| Working Cap Days ⓘ | 0 | 220 | 232 | 122 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 91 | 97 | 49 | 0 |
Return on Equity has increased versus last 3 years average to 7.10%
Sales growth is growing at healthy rate in last 3 years 103.71%
Net Profit is growing at healthy rate in last 3 years 70.00%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.2 | 1.7 |
| TTM Sales (₹ Cr.) | 51.3 | 62.5 |
| BVPS (₹.) ⓘ | 19.2 | 20.1 |
| Reserves (₹ Cr.) ⓘ | 9 | 9 |
| P/BV ⓘ | 2.29 | 2.19 |
| PE ⓘ | 37.16 | 26.12 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 41.3 |
| Equity (₹ Cr.) | 9.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 6.07 | 26.76 | 28.70 | 51.31 |
| Operating Expenses ⓘ | 5.61 | 25.70 | 27.92 | 49.55 |
| Manufacturing Costs | 0.06 | 0.22 | 0.20 | 0.23 |
| Material Costs | 4.27 | 20.97 | 24.53 | 45.91 |
| Employee Cost | 0.61 | 2.11 | 0.96 | 0.97 |
| Other Costs ⓘ | 0.68 | 2.39 | 2.23 | 2.44 |
| Operating Profit ⓘ | 0.46 | 1.06 | 0.78 | 1.76 |
| Operating Profit Margin (%) | 7.5% | 4.0% | 2.7% | 3.4% |
| Other Income ⓘ | 0 | 0.04 | 0.27 | 0.13 |
| Interest ⓘ | 0.18 | 0.48 | 0.34 | 0.21 |
| Depreciation ⓘ | 0.12 | 0.28 | 0.25 | 0.21 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.16 | 0.34 | 0.46 | 1.48 |
| Tax ⓘ | 0.01 | -0.08 | 0.16 | 0.37 |
| Profit After Tax | 0.15 | 0.42 | 0.29 | 1.11 |
| PAT Margin (%) | 2.5% | 1.6% | 1.0% | 2.2% |
| Adjusted EPS (₹) | 0.2 | 0.5 | 0.3 | 1.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 4.78 | 11.03 | 11.32 | 13.33 | ||||||
| Share Capital ⓘ | 3.34 | 4.54 | 4.54 | 4.70 | ||||||
| Reserves ⓘ | 1.44 | 6.49 | 6.78 | 8.64 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 4.51 | 3.06 | 2.85 | 0.32 | ||||||
| Long Term Debt | 2.63 | 1.60 | 1.03 | 0 | ||||||
| Short Term Debt | 1.89 | 1.46 | 1.83 | 0.32 | ||||||
| Trade Payables | 5.09 | 7.47 | 6.70 | 8.44 | ||||||
| Others Liabilities ⓘ | 1.28 | 1.58 | 0.83 | 1.29 | ||||||
| Total Liabilities ⓘ | 15.66 | 23.15 | 21.70 | 23.38 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 1.18 | 1.34 | 1.48 | 2.30 | ||||||
| Accumulated Depreciation | 0.12 | 0.40 | 0.65 | 0.82 | ||||||
| Net Fixed Assetsⓘ | 1.07 | 0.94 | 0.83 | 1.48 | ||||||
| CWIP ⓘ | 0 | 0 | 0.02 | 0.02 | ||||||
| Investmentsⓘ | 0.06 | 2.93 | 2.84 | 4.70 | ||||||
| Inventories | 4.33 | 5.93 | 6.04 | 5.03 | ||||||
| Trade Receivables | 7.16 | 9.11 | 8.78 | 10.09 | ||||||
| Cash Equivalents | 0.97 | 0.34 | 0.37 | 0.45 | ||||||
| Others Assetsⓘ | 2.07 | 3.89 | 2.83 | 1.61 | ||||||
| Total Assets ⓘ | 15.66 | 23.15 | 21.70 | 23.38 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 1.38 | -0.32 | 1.09 | 3.13 |
| PBT ⓘ | 0.16 | 0.34 | 0.46 | 1.48 |
| Adjustment ⓘ | 0.30 | 0.76 | 0.59 | 0.35 |
| Changes in Working Capital ⓘ | 0.92 | -1.34 | 0.12 | 1.42 |
| Tax Paid ⓘ | 0 | -0.07 | -0.08 | -0.11 |
| Cash Flow From Investing Activity ⓘ | -0.70 | -4.58 | 0.46 | -0.88 |
| Capex | -0.01 | -0.16 | -0.13 | -0.79 |
| Net Investments | -0.06 | -2.87 | 0.10 | -1.81 |
| Others ⓘ | -0.63 | -1.55 | 0.48 | 1.71 |
| Cash Flow From Financing Activityⓘ | -0.06 | 4.27 | -1.52 | -2.18 |
| Net Proceeds from Shares ⓘ | 1.71 | 5.84 | 0 | 0.91 |
| Net Proceeds from Borrowing ⓘ | -1.44 | -1.02 | -0.58 | -1.03 |
| Interest Paid ⓘ | -0.18 | -0.48 | -0.34 | -0.21 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | -0.14 | -0.06 | -0.60 | -1.86 |
| Net Cash Flow ⓘ | 0.62 | -0.63 | 0.03 | 0.07 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 3.29 | 5.37 | 2.64 | 9.03 | ||||||
| ROCE (%) | 3.41 | 6.44 | 5.36 | 11.98 | ||||||
| Asset Turnover Ratio | 0.39 | 1.38 | 1.28 | 2.28 | ||||||
| PAT to CFO Conversion(x) | 9.2 | -0.76 | 3.76 | 2.82 | Working Capital Days | |||||
| Receivable Days | 430 | 111 | 114 | 67 | ||||||
| Inventory Days | 261 | 70 | 76 | 39 | ||||||
| Payable Days | 435 | 109 | 105 | 60 | ||||||
It is manufacturing company with wide range of Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products. The company develops, manufactures and commercializes Herbo-Nutraceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under Nutraceuticals. It is also engage in trading of raw material used in manufacturing Nutraceutical products.
The company has product approvals under the license issued by FSSAI (Food Safety and Standards Authority of India) and AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy) department for manufacturing of Tablets, Capsules, Oral Liquids and Ointments and also for analysis of Chemical, Instrumental & Microbiology. It is holding WHO, HACCP, HALAL, Kosher and ISO 9001:2015 certificate issued by Independent agencies. It has also applied for patents of its three products. It has developed more than 100 formulations and 1000 brands for third party for domestic market under different segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Sports nutrition. It manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet, powders and effervescent tablets. The company manufacturing unit is located at 4-9, and 21 at Shyam Estate, Santej, Ta: Kalol, Gandhinagar.
Business area of the company
The company does third party manufacturing of Nutraceutical products on job work basis. The raw material is procured by it for which it receives order for manufacturing their semi-finished/finished Nutraceutical products. It also does marketing of products which are manufactured by it under its own brand. Its products are sold through whole seller distributors/ sales distribution channels. It is also engage in trading of raw material used in manufacturing Nutraceutical products. Such raw material is basically also raw material which is used in manufacturing of its own products.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
